title: Treatment of children with Henoch-Schönlein purpura nephritis with mycophenolate mofetil.
abstract: BACKGROUND
  Henoch-Schönlein purpura (HSP) can progress to Henoch-Schönlein purpura nephritis (HSPN), and the most effective management remains unclear. Our aim was to evaluate the efficacy of mycophenolate mofetil (MMF) for treating pediatric patients with HSPN and nephrotic-range proteinuria.
  
  
  METHODS
  Twelve children, seven boys and five girls, mean age 8.33 (range 6-12) years at the time of HSPN diagnosis with nephrotic-range proteinuria, were treated with MMF. All patients failed steroid treatment, and mean proteinuria at the time of MMF initiation was 5.6 g/d. MMF dosage ranged from 20 to 25 mg/kg per day. Patients also received an angiotensin-converting enzyme inhibitor (cliazapril) at MMF initiation. Mean follow-up was 3.9 (range 2.3-5.5) years.
  
  
  RESULTS
  All patients responded to MMF at a mean of 2.5 (range 1-4 months). Among the 12 patients, MMF was administered for 10 months in five, 12 months in six, and 15 months in one. At last follow-up, all patients had negative proteinuria and normal renal function, and no relapses were noted. No serious adverse effects of MMF were noted in any patient.
  
  
  CONCLUSIONS
  MMF is useful for treating pediatric patients with HSPN and nephrotic-range proteinuria.
authors.affiliation: Department of Pediatrics, Shengjing hospital of China Medical University, Shenyang, Liaoning, China. yue_du126@126.com
authors.forename: Yue
authors.initials: Y
authors.lastname: Du
authors.forename: Ling
authors.initials: L
authors.lastname: Hou
authors.forename: Chengguang
authors.initials: C
authors.lastname: Zhao
authors.forename: Mei
authors.initials: M
authors.lastname: Han
authors.forename: Yubin
authors.initials: Y
authors.lastname: Wu
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001706:Biopsy; D002648:Child; D003520:Cyclophosphamide / Q000627:therapeutic use; D004351:Drug Resistance; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D011695:IgA Vasculitis / Q000150:complications / Q000628:therapy*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007668:Kidney / Q000473:pathology; D007677:Kidney Function Tests; D007958:Leukocyte Count; D008297:Male; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009393:Nephritis / Q000209:etiology / Q000628:therapy*; D011507:Proteinuria / Q000209:etiology; D012189:Retrospective Studies; D013256:Steroids / Q000627:therapeutic use
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D007166:Immunosuppressive Agents; D013256:Steroids; D003520:Cyclophosphamide; D009173:Mycophenolic Acid
references.citation: Arch Med Res. 2006 Jan;37(1):68-73
references.pmid: 16314189
references.citation: Am J Kidney Dis. 2006 Jun;47(6):993-1003
references.pmid: 16731294
references.citation: Kidney Int. 2005 Aug;68(2):802-12
references.pmid: 16014059
references.citation: Pediatr Nephrol. 2011 Jun;26(6):921-5
references.pmid: 21373776
references.citation: Am J Kidney Dis. 2003 Dec;42(6):1114-20
references.pmid: 14655181
references.citation: Rheumatol Int. 2006 Oct;26(12):1078-83
references.pmid: 16736162
references.citation: Kidney Int. 2004 Dec;66(6):2411-5
references.pmid: 15569333
references.citation: Pediatr Nephrol. 2005 Aug;20(8):1087-92
references.pmid: 15889281
references.citation: ScientificWorldJournal. 2007 Jan 10;7:20-30
references.pmid: 17221139
references.citation: Drugs. 1996 Feb;51(2):278-98
references.pmid: 8808168
references.citation: Intern Med. 2005 Jun;44(6):611-5
references.pmid: 16020890
references.citation: Pediatr Nephrol. 2007 Oct;22(10):1717-22
references.pmid: 17647023
references.citation: Br Med J. 1977 Jul 2;2(6078):11-4
references.pmid: 871734
references.citation: Hypertension. 1999 Mar;33(3):862-8
references.pmid: 10082500
references.citation: Clin Nephrol. 2011 Apr;75(4):380-3
references.pmid: 21426894
references.citation: Indian J Pediatr. 2012 Feb;79(2):207-12
references.pmid: 21739306
references.citation: Pediatr Nephrol. 2010 Jan;25(1):19-26
references.pmid: 19526254
references.citation: Lupus. 2005;14 Suppl 1:s2-8
references.pmid: 15803924
references.citation: Scand J Urol Nephrol. 2008;42(2):178-80
references.pmid: 17853044
references.citation: Kidney Int. 2004 May;65(5):1842-9
references.pmid: 15086925
references.citation: Am J Nephrol. 2001 Mar-Apr;21(2):128-33
references.pmid: 11359020
references.citation: N Engl J Med. 1996 Apr 11;334(15):939-45
references.pmid: 8596594
references.citation: Int J Rheumatol. 2010;2010:254316
references.pmid: 20628492
references.citation: Pediatr Nephrol. 2003 Nov;18(11):1138-42
references.pmid: 12928858
references.citation: Am J Ther. 2010 Sep-Oct;17(5):e163-6
references.pmid: 19636243
references.citation: Scand J Rheumatol. 2005 Sep-Oct;34(5):392-5
references.pmid: 16234188
references.citation: Drugs. 2005;65(17):2429-36
references.pmid: 16296869
references.citation: Clin Nephrol. 2003 Aug;60(2):80-4
references.pmid: 12940608
references.citation: Pediatr Nephrol. 2003 Apr;18(4):347-50
references.pmid: 12700960
references.citation: Pediatr Nephrol. 2011 Mar;26(3):411-7
references.pmid: 21184240